The board of directors of Everest Medicines Limited announced that Mr. Xiaofan Zhan has resigned as an executive Director and the Chief Operating Officer of the Company with effect from 31 March 2023 to devote more time to his other business endeavours.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.75 HKD | +3.71% | -2.46% | +13.64% |
May. 14 | Calliditas Therapeutics Partner Offers Nefecon in China; Shares Rise | MT |
May. 14 | Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.64% | 940M | |
-2.99% | 89.49B | |
+2.50% | 40.67B | |
-12.01% | 33.15B | |
+62.80% | 26.45B | |
-19.79% | 14.69B | |
-8.58% | 12.89B | |
-12.34% | 11.54B | |
-43.92% | 11.34B | |
+3.82% | 8.84B |
- Stock Market
- Equities
- 1952 Stock
- News Everest Medicines Limited
- Everest Medicines Limited Announces Resignation of Xiaofan Zhan as an Executive Director and the Chief Operating Officer